Significantly, TINAGL1 is proposed as a profibrotic factor in HCV-infected patients after virological cure by treatment with DAAs and showed promising therapeutic potential in controlling liver fibrosis, providing an innovative target for the treatment of liver fibrosis after liver injury, including but not limited to HCV infection. Here, TINAGL1 is linked to Hepatic fibrosis.